Key statistics
As of last trade Belite Bio Inc (D01:DUS) traded at 156.00, -1.27% below its 52-week high of 158.00, set on Feb 25, 2026.
52-week range
| Open | 157.00 |
|---|---|
| High | 157.00 |
| Low | 153.00 |
| Bid | 156.00 |
| Offer | 168.00 |
| Previous close | 157.00 |
| Average volume | 2.86 |
|---|---|
| Shares outstanding | 37.51m |
| Free float | 34.41m |
| P/E (TTM) | -- |
| Market cap | 7.14bn USD |
| EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 12:05 GMT.
More ▼
Announcements
- Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results
- Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
- Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
- Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
- Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
- New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
- Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
- Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
More ▼
